We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+7.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.62B
AUM Growth
+$540M
(+18%)
Cap. Flow
+$569M
Cap. Flow
% of AUM
15.72%
Top 10 Holdings %
Top 10 Hldgs %
34.44%
Holding
132
New
36
Increased
34
Reduced
15
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$105M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$93.1M |
| 3 |
Medtronic
MDT
|
+$84.8M |
| 4 |
Nuvation Bio
NUVB
|
+$84.1M |
| 5 |
AbbVie
ABBV
|
+$77.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$137M |
| 2 |
Quest Diagnostics
DGX
|
+$94.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$87.1M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$57.5M |
| 5 |
Organogenesis Holdings
ORGO
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.31% |
| 2 | Financials | 0.29% |
| 3 | Industrials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sana Biotechnology
SANA
$916M
| $24.5M | 0.68% |
+732,321
| New | +$23.8M |
|
52
Immunocore
IMCR
$1.7B
| $23.4M | 0.65% |
+550,000
| New | +$24.5M |
|
53
Curis
CRIS
$9.41M
| $23.2M | 0.64% |
5,134
-721
| -12% | -$3.02M |
|
54
Aurinia Pharmaceuticals
AUPH
$1.92B
| $23.2M | 0.64% |
1,784,000
-216,000
| -11% | -$3.13M |
|
55
Cardiff Oncology
CRDF
$63.6M
| $22.7M | 0.63% |
2,447,700
+840,700
| +52% | +$10.2M |
|
|
IGMS
56
DELISTED
IGM Biosciences
IGMS
| $22.5M | 0.62% |
293,000
+213,000
| +266% | +$19.4M |
|
57
Bolt Biotherapeutics
BOLT
$7.72M
| $21.5M | 0.59% |
+32,715
| New | +$21.3M |
|
|
CMRX
58
DELISTED
Chimerix, Inc.
CMRX
| $21.5M | 0.59% |
+2,230,000
| New | +$20.5M |
|
|
GRTS
59
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $20M | 0.55% |
2,122,064
| – | – |
|
60
Bioventus
BVS
$895M
| $19.2M | 0.53% |
+1,254,333
| New | +$17.9M |
|
|
SGTX
61
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $19M | 0.53% |
65,459
+12,536
| +24% | +$4.98M |
|
62
SI-BONE Inc
SIBN
$795M
| $18.4M | 0.51% |
577,570
-62,314
| -10% | -$1.92M |
|
63
Collegium Pharmaceutical
COLL
$1.16B
| $17.5M | 0.48% |
740,000
-499,000
| -40% | -$11.9M |
|
|
ONCS
64
DELISTED
OncoSec Medical Incorporated
ONCS
| $16.6M | 0.46% |
157,727
+69,000
| +78% | +$9.44M |
|
|
ALPN
65
DELISTED
Alpine Immune Sciences Inc
ALPN
| $16M | 0.44% |
1,511,000
+263,000
| +21% | +$3.28M |
|
|
PHAS
66
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $14.8M | 0.41% |
+4,285,000
| New | +$17.4M |
|
|
KZR
67
DELISTED
Kezar Life Sciences
KZR
| $11.4M | 0.31% |
+190,708
| New | +$11.1M |
|
68
Pharvaris
PHVS
$2.35B
| $11.2M | 0.31% |
+400,000
| New | +$12.6M |
|
|
ADMS
69
DELISTED
Adamas Pharmaceuticals
ADMS
| $10.6M | 0.29% |
+2,200,200
| New | +$11.5M |
|
|
AFMD
70
DELISTED
Affimed
AFMD
| $10.3M | 0.28% |
+129,600
| New | +$8.41M |
|
|
MRUS
71
DELISTED
Merus
MRUS
| $10.2M | 0.28% |
+487,000
| New | +$11.2M |
|
72
SCYNEXIS
SCYX
$36M
| $10M | 0.28% |
157,971
+1,096
| +0.7% | +$71.9K |
|
73
Instil Bio
TIL
$49.4M
| $10M | 0.28% |
+20,000
| New | +$10.3M |
|
74
Immatics
IMTX
$1.19B
| $9.92M | 0.27% |
+884,600
| New | +$10M |
|
|
TERN
75
DELISTED
Terns Pharmaceuticals
TERN
| $8.8M | 0.24% |
+400,000
| New | +$8.77M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q1 2021 Portfolio in Review
As of Q1 2021, Avidity Partners Management held 132 positions worth $3.62B, up 18% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Avidity Partners Management deployed $569M of net new capital in Q1 2021, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Intuitive Surgical: 418,200 shares worth $103M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Organogenesis Holdings, an estimated $55M trimmed.
- Avidity Partners Management's largest Q1 2021 buy was Intuitive Surgical: 418,200 shares worth $103M.
- Avidity Partners Management added most to Medtronic in Q1 2021, an estimated $84.8M increase.
- Avidity Partners Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $55M.
- Avidity Partners Management fully exited Eli Lilly in Q1 2021, selling an estimated $137M.
- Avidity Partners Management's ten largest holdings make up 34% of its $3.62B portfolio in Q1 2021.
- Avidity Partners Management opened 36 new positions and closed 38 in Q1 2021.
- Avidity Partners Management's portfolio value rose 18% quarter-over-quarter to $3.62B.
Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.